In vitro antimyeloma activity of the iron chelator deferasirox (DFX).

被引：0
|
作者：
Willenbacher, Ella [1 ]
Willenbacher, Wolfgang [1 ]
Funk, Ulrike [1 ]
Kircher, Brigitte [1 ]
机构：
[1] Med Univ Innsbruck, A-6020 Innsbruck, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19587
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells
    Tataranni, Tiziana
    Agriesti, Francesca
    Mazzoccoli, Carmela
    Ruggieri, Vitalba
    Scrima, Rosella
    Laurenzana, Ilaria
    D'Auria, Fiorella
    Falzetti, Franca
    Di Ianni, Mauro
    Musto, Pellegrino
    Capitanio, Nazzareno
    Piccoli, Claudia
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 170 (02) : 236 - 246
  • [42] Iron chelator deferasirox rescued mice from Fas-induced fulminant hepatitis
    Sato, Tsutomu
    Kobune, Masayoshi
    Murase, Kazuyuki
    Kado, Yukari
    Okamoto, Tetsuro
    Tanaka, Shingo
    Kikuchi, Shohei
    Nagashima, Hiroyuki
    Kawano, Yutaka
    Takada, Kohichi
    Iyama, Satoshi
    Miyanishi, Koji
    Sato, Yasushi
    Takimoto, Rishu
    Kato, Junji
    HEPATOLOGY RESEARCH, 2011, 41 (07) : 660 - 667
  • [43] The new oral iron chelator, Deferasirox, is the new drug to prevent Liver Fibrosis and Hepatocarcinogenesis
    Yamamoto, Naoki
    Yamasaki, Takahiro
    Uchida, Koichi
    Tanabe, Norikazu
    Takami, Taro
    Saeki, Issei
    Fujisawa, Koichi
    Maeda, Masaki
    Terai, Shuji
    Sakaida, Isao
    HEPATOLOGY, 2013, 58 : 1084A - 1085A
  • [44] Hyperchloraemic metabolic acidosis induced by the iron chelator deferasirox: a case report and review of the literature
    Dell'Orto, V. G.
    Bianchetti, M. G.
    Brazzola, P.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (06) : 526 - 527
  • [45] Kinetic aspects of iron(III)-chelation therapy with deferasirox (DFX) revealed by the solvolytic dissociation rate of the Fe(III)-DFX complex estimated with capillary electrophoretic reactor
    Suzuki, Ryota
    Iki, Nobuhiko
    JOURNAL OF INORGANIC BIOCHEMISTRY, 2023, 241
  • [46] The Oral Iron Chelator Deferasirox Induces Apoptosis in Myeloid Leukemia Cells by Targeting Caspase
    Kim, Jung-Lim
    Kang, Han-Na
    Kang, Myoung Hee
    Yoo, Young A.
    Kim, Jun Suk
    Choi, Chul Won
    ACTA HAEMATOLOGICA, 2011, 126 (04) : 241 - 245
  • [47] The oral iron chelator, deferasirox, may be a novel potential therapeutic agent for pancreatic cancer
    Harima, Hirofumi
    Kaino, Seiji
    Shinoda, Shuhei
    Kawano, Michitaka
    Suenaga, Shigeyuki
    Yamamoto, Naoki
    Yamasaki, Takahiro
    Sakaida, Isao
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 34 - 34
  • [48] Transfusion-Induced Impairment of Macrophage Responses Is Partially Restored By the Iron Chelator Deferasirox
    Vinchi, Francesca
    Sparla, Richard
    Passos, Sara
    Weidner, Heike
    Rauner, Martina
    Platzbecker, Uwe
    Muckenthaler, Martina U.
    BLOOD, 2018, 132
  • [49] The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers
    Tury, Sandrine
    Assayag, Franck
    Bonin, Florian
    Chateau-Joubert, Sophie
    Servely, Jean-Luc
    Vacher, Sophie
    Becette, Veronique
    Caly, Martial
    Rapinat, Audrey
    Gentien, David
    de la Grange, Pierre
    Schnitzler, Anne
    Lallemand, Francois
    Marangoni, Elisabetta
    Bieche, Ivan
    Callens, Celine
    JOURNAL OF PATHOLOGY, 2018, 246 (01): : 103 - 114
  • [50] Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells
    Kim, Dae Sik
    Na, Yoo Jin
    Kang, Myoung Hee
    Yoon, Soo-Young
    Choi, Chul Won
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2016, 31 (02): : 357 - 366
12345